Sign inCreate account

Report workspace tools

NCT00965497COMPLETEDanonymous

An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis

Sponsor

Source record

University of South Carolina

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.

Indication / condition

AI-normalized

Major Depression

Intervention

Source record

escitalopram

Source & freshness

Source record

NCT ID

NCT00965497

Original source

ClinicalTrials.gov

Source last updated

May 01, 2019

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00965497

Title

An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis

Sponsor

University of South Carolina

Status

COMPLETED

Phase

Phase 3

Condition raw

Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis

Condition normalized

Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.

Target normalized

Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.

Interventions

escitalopram

Public preview

Source record

Escitalopram (Lexapro) is being evaluated for its efficacy in treating major depressive disorder in patients with comorbid Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Given the increasing recognition of mental health issues in chronic neurological conditions, this study addresses an unmet need in the market. The potential to expand Lexapro's indications could enhance its market position against competitors in the antidepressant space, particularly those targeting similar patient populations. The results may influence prescribing practices and reimbursement policies, thereby impacting market access and commercial strategy for the product.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00965497

Status

COMPLETED

Phase

Phase 3

Sponsor

University of South Carolina

Executive brief

Investment-Ready Snapshot

Escitalopram (Lexapro) is being evaluated for its efficacy in treating major depressive disorder in patients with comorbid Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Given the increasing recognition of mental health issues in chronic neurological conditions, this study addresses an unmet need in the market. The potential to expand Lexapro's indications could enhance its market position against competitors in the antidepressant space, particularly those targeting similar patient populations. The results may influence prescribing practices and reimbursement policies, thereby impacting market access and commercial strategy for the product.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 01, 2019
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00965497

Indication

Major Depression

Modality

small molecule

Target

Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.

Intervention

escitalopram

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.